OBSV News and Press, ObsEva SA From 06/04/20

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) , a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of...

Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an upda...

This article was selected to be shared with PRO subscribers, who also got 7 days' exclusive access to Elle Investments’ original Top Idea on ObsEva (OBSV). Elle Investments is a small family office that manages its portfolio using a “quantamental” approach. F...

Note: A glossary of abbreviated terms is included at the end of the article. Calculations may not appear exact due to rounding. Investment Thesis Summary After hitting $18.00/share in September 2018, ObsEva (OBSV) shares began a long decline and now trade under $3.00/share. Even assign...

Gainers: TRUE   +4.7% .   INN   +4.4% . OBSV   +4.2% . KC   +4.1% . UA   +2.9% . More news on: TrueCar, Inc., Summit Hotel Properties, Inc., ObsEva SA, Stocks on the move, , Read more ...

  Geneva, Switzerland and Boston, MA – May 8, 2020  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...

Gainers: Portola Pharmaceuticals (NASDAQ: PTLA ) +130% . More news on: Portola Pharmaceuticals, Inc., CleanSpark, Inc., Genprex, Inc., Stocks on the move, , Read more ...

ObsEva (NASDAQ: OBSV ): Q1 Non-GAAP EPS of -$0.48 misses by $0.01 . More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news, , Read more ...

  No impact from COVID-19 expected on timing of PRIMROSE 1 and 2 and PROLONG trial readouts, enrollment of new patients in EDELWEISS 2 and 3 on temporary hold Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month data on track for Q2:20...

ObsEva SA (NASDAQ: OBSV ) perks up  4%  after hours on the heels of its announcement of the online publication of two abstracts detailing 52-week data on linzagolix in women endometriosis-related pain. The results, first  reported in June 2018, were generated in the Phase 2...